ICD-10 Coding for Metastatic Pancreatic Cancer(C25.9, C25.9B, C25.9M)
Learn about ICD-10 coding for metastatic pancreatic cancer, including primary and secondary site codes, sequencing rules, and documentation requirements.
Complete code families applicable to Metastatic Pancreatic Cancer
Compare key differences between these codes to ensure accurate selection
| Code | Description | When to Use | Key Documentation |
|---|---|---|---|
| C25.9 | Malignant neoplasm of pancreas, unspecified | Use when the primary site of pancreatic cancer is unspecified or generalized. |
|
| C78.89 | Secondary malignant neoplasm of other specified sites | Use when documenting metastasis from pancreatic cancer to other specified sites. |
|
Clinical Decision Support
Always review the patient's clinical documentation thoroughly. When in doubt, choose the more specific code and ensure documentation supports it.
Key Information
Essential facts and insights aboutMetastatic Pancreatic Cancer
Alternative codes to consider when ruling out similar conditions
Documentation & Coding Risks
Avoid these common issues when documenting Metastatic Pancreatic Cancer.
Using history codes for active treatment
Impact
Clinical: Misrepresentation of active disease status., Regulatory: Non-compliance with coding guidelines., Financial: Potential loss of reimbursement for active treatment.
Mitigation
Verify treatment status before coding., Use active codes until treatment concludes.
Incorrect sequencing of primary and secondary codes
Impact
Reimbursement: Incorrect DRG assignment, affecting reimbursement., Compliance: Non-compliance with ICD-10 sequencing rules., Data Quality: Inaccurate data on cancer treatment focus.
Mitigation
Sequence secondary code first if treatment focus is on metastasis.
Incorrect primary site coding
Impact
Using unspecified codes when primary site is known.
Mitigation
Ensure documentation specifies primary site whenever possible.